Abstract
Variable proportions of hematopoietic cells that are heterozygous or homozygous for the JAK2 (V617) mutation can be found in patients with myeloproliferative neoplasms. In this perspective article, Dr. Passamonti and Rumi discuss the biologic and clinical significance of the mutant allele burden. See related paper on page 38.